Subscribe
Subscribe today to receive CGD’s latest newsletters and topic updates.
All Commentary
Filters:
Topics
Facet Toggle
Content Type
Facet Toggle
Blog Type
Facet Toggle
Time Frame
Facet Toggle
Blog Post
March 27, 2024
Today marks a significant milestone as the Bill & Melinda Gates Foundation (BMGF) announces a new Open Access policy, representing a departure from traditional practices. This policy will cease support for individual article publishing fees, known as APCs, and mandate the use of preprints while advo...
Blog Post
November 08, 2023
How stable do emerging markets look now, in 2023? Which countries would be most and least resilient if another global adverse shock were to happen? A simple indicator constructed from a small set of economic and institutional variables was able to identify in 2019, prior to the COVID-19 pandemic and...
Blog Post
October 11, 2023
Budget support offers direct financing to a country’s treasury to create more “fiscal space” for public programs. It has constituted some 14 percent of ODA on average, increasing to over 20 percent in times of crisis. No aid modality is more controversial. Critics argue that, without earmarking fund...
Blog Post
October 05, 2023
A year ago, the International Monetary Fund (IMF) announced that an alarming 60 percent of developing countries and 25 percent of emerging market economies were either in debt distress or at severe risk of default. The confluence of severe shocks in the period 2020-22, starting with the COVID-19 pan...
Blog Post
September 27, 2023
The UK is, hopefully, coming out of its nadir in international development. This is marked by planned rises in development spend, an ambitious new international development white paper, a supportive Minister, and a new parliament in 2024. But before considering any proposal, future governments with ...
Blog Post
September 05, 2023
Today the Africa Centers for Disease Control’s (ACDC) Health Economics Programme (HEP) has published a new policy brief on the cost-effectiveness of two COVID-19 oral antivirals (COAVs), a nirmatrelvir/ritonavir combination, developed by Pfizer and sold under the name Paxlovid, and Molnupiravir, dev...